Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 2657-2665

  Ozaki, Tomohiro ^a   Tamura, Kenji ^a,d   Satoh, Taroh ^b   Kurata, Takayasu ^c   Shimizu, Toshio ^a   Miyazaki, Masaki ^b   Okamoto, Isamu ^b   Nakagawa, Kazuhiko ^b   Fukuoka, Masahiro ^b  

^a KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Docetaxel; Gastric cancer; Phase I study; S 1; Weekly chemotherapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CARBOPLATIN; DOCETAXEL; FLUOROURACIL; IRINOTECAN; PACLITAXEL; UFT;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; STOMACH NEOPLASMS; TAXOIDS; TEGAFUR;

EID: 34547729862     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 55: 10-30, 2005.
2. Pyrhonen S, Kuitunen T, Nyandoto P and Kouri M: Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71: 587-591, 1995.
3. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA and Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72: 37-41, 1993.
4. Glimelius B, Hoffman K, Haglund U, Nyren O and Sjoden PO: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5: 189-190, 1994.
5. Macdonald JS, Schein PS, Wooley PV, Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht C, Brunet R and Lagarde C: 5-fluorouracil, doxorubinicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93: 533-536, 1980.
6. Klein HO, Wickramanayake PD, Dieterle F, Mohr R, Oerkermann H and Gross R: High-dose MTX/5-FU and adriamycin for gastric cancer. Semin Oncol 10: 29-31, 1983.
7. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer HJ and Buente H: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7: 1310-1317, 1989.
8. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N and Ford H: A phase II study in advanced gastroesophageal cancer using epirubicin and cisplatin in combination with infusion 5-fluorouracil (ECF). Ann Oncol 5: 609-616, 1994.
9. Moertel CG, Rubin J, O'Connell MJ, Schutt AJ and Wieand HS: A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4: 1053-1057, 1986.
10. Lacave AJ, Baron FJ, Anton LM, Estrada E, De Sande LM, Palacio I, Esteban E, Gracia JM, Buesa JM, Fernandez OA and Gonzalez Baron M: Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol 2: 751-754, 1991.
11. Ohtsu A, Yoshida S, Saito D, Shimada Y, Miyamoto K, Fujii T, Yoshino M and Yoshimori M: An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer. Jpn J Clin Oncol 21: 120-124, 1991.
12. Ohtsu A, Shimada Y, Yoshida S, Saito H, Seki S, Morise K and Kurihara M: Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer 30A: 2091-2093, 1994.
13. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996.
14. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of the novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998.
15. Koizumi W, Kurihara M, Nakano S and Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58: 191-197, 2000.
16. Chollet P, Schoffski P, Weigang-Kohler K, Schellens JH, Cure H, Pavlidis N, Grunwald V, De Boer R, Wanders J and Fumoleau P, EORTC Early Clinical Studies Group: Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 39: 1264-1270, 2003.
17. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M and Urrea P: Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23: 6957-6965, 2005.
18. Inokuchi M, Yamashita T, Yamada H, Kojima K, Ichikawa W, Nihei Z, Kawano T and Sugihara K: Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer 94: 1130-1135, 2006.
19. Ringel I and Horwitz SB: Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288-291, 1991.
20. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders J, Franklin H, LeBail N and Verweij J: Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 70: 380-383, 1994.
21. Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA and Benson III AB: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 13: 87-93, 1996.
22. Taguchi T, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J and Hirabayashi N: Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A). Jpn J Cancer Chemothr 25: 1915-1924, 1998.
23. Mai M, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, Hirabayashi N, Taguchi T and Furue: A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B). Jpn J Cancer Chemother 26: 487-496, 1999.
24. Bissery MC, Nohynek G, Sanderink GJ and Lavelle F: Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drug 6: 339-368, 1995.
25. Park YH, Ryoo B-Y, Choi S-J and Kim H-T: A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 90: 1329-1333, 2004.
26. Chun JH, Kim HK, Lee JS, Choi JY, Hwangbo B, Lee HG, Park SR, Choi IJ, Kim CG, Ryu KW, Kim YW, Lee JS and Bae JM: Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 28: 188-194, 2005.
27. Yoshioka T, Sakata Y, Terashima M, Sekikawa K, Gamoh M, Mitachi Y, Saitoh S and Kanamaru R: Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer. Gastric Cancer 6: 153-158, 2003.
28. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M and Goldhirsch A: Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Ann Oncol 11: 301-306, 2000.
29. Moiseyenko VM, Ajani JA, Tjiulandin SA, Majlis A, Constenla M, Boni C, Anelli A, Yver AJ and Van Cutsem E, on behalf of the TAX 325 Study Group: Final results of a randomized controlled phase III trial (TAX325) comparing docetaxel (T) combined with cisplatin and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). Proc Am Soc Clin Oncol 23: 308s (abstract 4002), 2005.
30. Fukushima M, Satake H and Uchida J: Preclinical antitumor efficacy of S1: a new oral formulaton of 5-fluorouracil on human tumor xenografts. Int J Oncol 13: 693-698, 1998
31. Takahashi I, Emi Y, Kakeji Y, Uchida J, Fukushima M and Maehara Y: Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclinical study using gastric cancer xenografts. Oncology 68: 130-137, 2005.
32. Wada Y, Yoshida K, Suzuki T, Mizuiri H, Konishi K, Ukon K, Tanabe K, Sakata Y and Fukushima M: Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer 119: 783-791, 2006.
33. Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H, Komatsu Y, Kato T, Saitoh S, Akiya T, Munakata M, Miyata Y, Maeda Y, Takiuchi H, Nakano S, Esaki T, Kinjo F and Sakata Y: Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 94: 1803-1808, 2006.
34. Yoshida K, Hirabayashi N, Takiyama W, Ninomiya M, Takakura N, Sakamoto J, Nishiyama M and Toge T: Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res 24: 1843-1852, 2004.
35. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J and Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12: 3402-3407, 2006.
36. Tomiak E, Piccart MJ, Kerger J, Lips S, Awada A, de Valeriola D, Ravoet C, Lossignol D, Soulier JP and Auzannet V: Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 12: 1458-1467, 1994.
37. Graziano F, Catalano V, Baldelli AM, Giordani P, Testa E, Lai V, Catalano G, Battelli N and Cascinu S: A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 10: 1263-1266, 2000.
38. National Cancer Institute: The revised common toxicity criteria: version 2.0 CTEP website http://ctep.info.nih.gov, 1999.
39. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000.